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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARYTo harness the potential of human pluripotent stem cells (hPSCs), an abundant supply of their progenies is required. Here, hPSC expan-
sion as matrix-independent aggregates in suspension culture was combined with cardiomyogenic differentiation using chemical Wnt
pathway modulators. A multiwell screen was scaled up to stirred Erlenmeyer flasks and subsequently to tank bioreactors, applying
controlled feeding strategies (batch and cyclic perfusion). Cardiomyogenesis was sensitive to the GSK3 inhibitor CHIR99021 concentra-
tion, whereas the aggregate size was no prevailing factor across culture platforms. However, in bioreactors, the pattern of aggregate for-
mation in the expansion phase dominated subsequent differentiation. Global profiling revealed a culture-dependent expression of BMP
agonists/antagonists, suggesting their decisive role in cell-fate determination. Furthermore, metallothionein was discovered as a poten-
tially stress-related marker in hPSCs. In 100 ml bioreactors, the production of 40million predominantly ventricular-like cardiomyocytes
(up to 85% purity) was enabled that were directly applicable to bioartificial cardiac tissue formation.INTRODUCTION
Cardiovascular disorders can induce severe, progressive loss
of contractileheartmuscle tissue, includingbillionsof cardi-
omyocytes (CMs). Because of the low regenerative capacity
of the heart, this can ultimately lead to heart failure with
very limited treatment options available at present (Donn-
dorf et al., 2013). Given their proliferation and differentia-
tion potential, human pluripotent stem cells (hPSCs),
including embryonic stemcells (hESCs) and inducedplurip-
otent stem cells (hiPSCs), are an attractive cell source for the
mass generation of lineage- and (potentially) patient-spe-
cific progenies, including bona fide CMs (Laflamme and
Murry, 2011). This possibility opens new avenues for the
development of regenerative cell therapies and more spe-
cificdrugdiscovery assays. Therapeutic and industrial appli-
cations of hPSCs, however, will require large cell quantities
to be generated under highly robust, well-defined, and
economically viable conditions (Zweigerdt, 2009).
It was recently shown that hPSCs can be expanded as
cell-only aggregates in serum-free suspension culture irre-1132 Stem Cell Reports j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 Thspective of matrix supplementation (Amit et al., 2011; Ol-
mer et al., 2010; Singh et al., 2010), which is mandatory for
conventional surface-attached propagation of hPSCs. In
contrast to matrix-attached 2D conditions, suspension cul-
ture (3D) provides a straightforward strategy for process
upscaling, including cell cultivation in stirred tank bioreac-
tors (Couture, 2010). Stirred tank reactors represent a uni-
versal, well-established vessel type for the production of
recombinant proteins in industrial biotechnology (Car-
rondo et al., 2012) and allow for cost-effective, multipara-
metric monitoring and optimization of mammalian cell
culture processes (Bulnes-Abundis et al., 2013). Once estab-
lished, relative linear process upscaling is feasible since
reactors from 0.1 to >1.000 l culture scale are available.
However, the application of stirred bioreactors to hPSC
expansion and their differentiation is still in its infancy.
Single cell-based inoculation of suspension cultures es-
tablishes a well-controlled starting point at every passage
(Zweigerdt et al., 2011). The inoculation density as well
as the physical properties of the culture system (such as
the reactor design and the stirring speed) can then bee Authors
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sequent growth (Olmer et al., 2012; Schroeder et al., 2005).
Importantly, when utilizing appropriate media such as
mTeSR, hPSCs remain pluripotent over multiple passages
in aggregate culture (Olmer et al., 2010; Zweigerdt et al.,
2011), thus providing the attractive option of directly
switching from hPSC expansion to lineage-specific differ-
entiation in a continuous suspension process.
Recent work has demonstrated thatWnt pathwaymodu-
lation by small molecules is an efficient strategy for hPSC
cardiomyogenic induction, resulting in 60%–80% CMs
content in defined media (Gonzalez et al., 2011; Lian
et al., 2012; Minami et al., 2012). A common feature of
these protocols is the activation of the Wnt pathway at
early stages of differentiation by the GSK3 inhibitor
CHIR99021 (CHIR) aiming at enhanced mesoderm induc-
tion. Following cues from developmental biology, Wnt
pathway activity is then inhibited using inhibitors such
as IWP (inhibitor of Wnt production) or IWR (inhibitor
of Wnt response). This later step aims at specifying cardiac
differentiation of the mesoderm-directed cells (Hudson
et al., 2012; Lian et al., 2012; Ren et al., 2011; Willems
et al., 2011). However, these protocols rely on confluent
monolayer cultures limiting straightforward industrial
scale production.
In this study, we aimed at directly combining hPSC
expansion with cardiomyogenic differentiation in suspen-
sion culture. Taking advantage of a NKX2.5-GFP reporter
line (Elliott et al., 2011), a multiwell screening assay was
established to develop Wnt modulator-based CMs differ-
entiation of hPSC aggregates in static suspension culture.
By scaling up to rotated Erlenmeyer flasks and ultimately
to fully equipped stirred tank bioreactors, we show the
robustness of the method, as well as its applicability to dy-
namic suspension culture. The work provides insights on
critical cellular and molecular process parameters and a
straightforward strategy for the scalable mass production
of CMs at up to 85% purity, which predominantly dis-
played ventricular-like action potentials (APs). Moreover,
bioreactor-derived embryoid bodies (EBs) were directly
applicable for the generation of human bioartificial car-
diac tissue (BCT) (Kensah et al., 2011), a promising strat-
egy for heart repair and novel in vitro drug discovery
and drug safety assays.RESULTS
Multiwell Screen Reveals Tight CHIR Concentration
Dependence of Cardiomyogenic Differentiation in
Suspension Culture
To establish combined hPSC expansion and cardiac differen-
tiation, single cell-dissociated HES3 NKX2-5eGFP/w wereStem Cell Repseeded into 12-well dishes in mTeSR1 (Figure 1A). After
4 days, a reproducible pattern of floating aggregates (214 ±
65mmaveragediameter; FiguresS1AandS1Bavailableonline)
formedcomprising1millioncellsperwell (datanotshown);
98% TRA-1-60 positivity (Figure S1C) suggested mainte-
nance of pluripotency in this culture format, in linewith pre-
vious findings (Olmer et al., 2010; Zweigerdt et al., 2011).
mTeSR1was replaced with differentiationmedium (3ml/
well; 0.33 million cells/ml) supplemented with 0–15 mM
CHIR for 24 hr, followed by IWP2 supplementation on
day 3 for 48 hr (Figure 1A). On day 10, fluorescence micro-
scopy of floating EBs and flow cytometry revealed the high-
est content of 52%± 7.3%NKX2.5-GFP-positive cells (GFP+;
indicative of CMs) at 7.5 mMCHIR (Figures 1B and 1C). The
highest total cell count was also observed under these con-
ditions (Figure 1D). Somewhat lower cell yields and GFP+
cells were obtained at 5 mM CHIR, whereas significantly
lower CMs induction was observed at 10 mM CHIR, which
further declined in response to higher drug concentrations
(Figures 1B–1D). In DMSO controls (0 mMCHIR), EBs disin-
tegrated over time, suggesting loss of vital cells (Figure 1B).
Replacing IWP2 by the alternative Wnt pathway inhibi-
tor IWR1 resulted in a shift toward reduced GFP+ cells at
5 mM but elevated GFP+ at 10 mMCHIR (Figure S1M). How-
ever, cardiomyogenic induction remained highest at
7.5 mM CHIR, resulting in 58.7% ± 8.8% GFP+ irrespective
of IWR1 or IWP2. Thus, IWP2 was maintained throughout
further experiments.
The established protocol was robust in experimental re-
peats and confirmed by two human iPSC lines differenti-
ated at 7.5 mM CHIR. Immunofluorescence and flow
cytometry specific to cardiac troponin T (cTNT), sarcomeric
a-actinin, myosin heavy chain (MHC), and NKX2.5,
respectively, revealed the induction of up to 60% CMs
in these hiPSC lines (Figures 1E and 1F).
The Static Suspension Protocol Is Scalable to Rotated
Erlenmeyer Flasks
Dynamic conditions can have a profound impact on stem
cell culture and differentiation (Fridley et al., 2012). We
thus tested whether the static 12-well format can be
directly transferred to rotated Erlenmeyer flasks (Figure 2A).
In single cell-inoculated flasks, a relatively fast increase in
aggregate size during the initial 48 hr was observed (data
not shown) and aggregates with an average diameter of
389.4 ± 13.8 mm formed in 4 days, with 98% of cells re-
maining TRA-1-60 positive (Figures S1D and S1F). Differen-
tiation by 7.5 mM CHIR resulted in robust GFP expression
and formation of contractile EBs (Figure 2B). CM induction
was confirmed by immunohistochemistry specific to sarco-
meric markers on EB-derived sections and dissociated cells
(Figure 2C). On average, 55% ± 7.4% GFP+ cells were ob-
tained on days 7–10 (Figure 2D) with >60% positivity toorts j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 The Authors 1133
Figure 1. Efficient Cardiomyogenic Differentiation in Static Suspension Culture Works Only in a Tight Range of CHIR Concentration
(A) Scheme of the expansion/differentiation protocol in a 12-well format.
(B) Microscopic assessment of NKX2.5-GFP transgenic HES3 EBs on day 10 in response to the respective CHIR concentration supplemented
for 24 hr at day 0.
(C) Flow cytometry on day 10 revealed the highest content of GFP+ cells at 7.5 mM CHIR (n = 3 independent experiments, mean ± SEM).
(D) Bars represent the total cell count per well and respective GFP content (green), confirming 7.5 mM CHIR as the most efficient con-
centration for CM induction (n = 3 experiments, mean ± SEM).
(legend continued on next page)
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tively (Figure 2E).
Alternative Feeding Strategies Impact on Aggregate
Formation in Stirred Bioreactors
To increase the production of CMs, we moved our com-
bined expansion/differentiation protocol to 100 ml stirred
bioreactors and examined two alternative expansion strate-
gies. First, we attempted ‘‘batch-feeding’’ (batch), in which
cells were allowed to form stirring-controlled aggregates for
48 hr before 100 ml mTeSR1 was exchanged daily. The
strategy resulted in a relative linear increase of ‘‘batch-
aggregates’’ (BAs) in size over time (Figures 3A and 3B), in
line with published observations (Olmer et al., 2012).
The second strategy termed ‘‘cyclic perfusion feeding’’
(C-perfusion) aimed at more homogeneous culture condi-
tions by continuous, automated medium exchange: at
24 hr after inoculation, stirring was paused for 10 min
every 2 hr to let cell aggregates settle by gravity. About
7 ml of medium was automatically replaced at every cycle,
resulting in a turnover of 90 ml/day (approximately
equivalent to the 100 ml daily medium throughput by
batch). Online monitoring of metabolic activity by means
of dissolved oxygen (DO) and pH revealed that both pa-
rameters remained more stable in C-perfusion compared
with batch culture (Figure S2). The pattern of C-perfusion
aggregate (CPA) formation was also different, as relatively
large spheres readily formed at an early stage (Figures 3A
and 3B), reminiscent of the Erlenmeyer flask approach.
Such process-dependent aggregate patterns were reproduc-
ible in individual runs (Figure 3B), resulting in 283 ±
9.6 mm average diameter for BAs compared with 468 ±
14.4 mm for CPAs on day 0 (compare Figures S1G and
S1H with Figures S1J and S1K). Notably, the pluripotency
markers TRA-1-60 (Figures 1I and 1L), NANOG, and OCT4
(quantitative RT-PCR [qRT-PCR]; Figure 3F) had similar
expression profiles in both culture conditions.
Global gene expression analysis comparing the undiffer-
entiated aggregates derived from batch and C-perfusion on
day 0 revealed a highly equivalent expression signature of
established pluripotency, as well as cell proliferation genes
and primitive-streak markers (Figure S3A). To identify po-
tential differences, array data were processed in a group
comparison by the programs Qlucore Omics and RCUTAS,
filtering for genes that were statistically significant and
>2-fold regulated, respectively (see respective gene lists in
Figures S3B–S3D). A set of 21 genes was found to be upregu-(E and F) Differentiation of the hiPSC lines hHSC_F1285T_iPS2 and h
protocol, as shown by microscopic images of plated cells derived from
in blue; scale bars represent 100 mm) and flow cytometry of d10 E
(F) Isotype controls in gray.
See also Figure S1.
Stem Cell Replated in BAs by both programs (Figure 3C). Notably, these
included six members of the metallothionein family
(MT1M, MT2A, MT1H, MT1L, MT1E, MT1B), known to
bind metal ions (gene ontology categories: cellular
response to zinc ion,metal ion, inorganic substances, nega-
tive regulation of growth). In CPAs, only three genes were
found to be upregulated under the same comparative
criteria: the TGF-beta superfamily member BMP2, the
caudal type homeobox transcription factor (CDX4), and
the melanin-concentrating hormone receptor 1 (MCHR1;
Figure 3C). Exemplary verification of the array data
confirmed upregulation of BMP2 in CPAs and MT1M in
Bas, as depicted in Figure S3E.
The Preceding Expansion Strategy Determines
Differentiation Outcome in Bioreactors
Before inducing aggregate differentiation, cell numbers
were determined. On average, batch expansion yielded
79 million HES3-NKX2-5eGFP/w cells per bioreactor,
whereas 60 million cells were recovered by C-perfusion
(n = 2 runs each; data not shown). Subsequently, aggregates
were diluted in differentiation medium (7.5 mM CHIR) to
establish 33 million cells per 100 ml (0.33 million
cells/ml equivalent to 12-well cultures) per bioreactor. After
this ‘‘equalization step,’’ the same differentiation scheme
(Figure 3D) was applied in stirred reactors irrespective of
the preceding expansion strategy. Surprisingly, we found
that differentiation runs (n = 3) initiated with BAs repeat-
edly failed to form contracting EBs and essentially no
GFP+ cells were detected (Figure 3E). In contrast, contract-
ing EBs were observed upon CPAs differentiation, which
was accompanied by GFP expression in all experimental re-
peats (n = 3; Figure 3E).
NANOG and OCT4 expression was equivalent in both
expansion approaches before differentiation (day 0; Fig-
ure 3F). However, after 24 hr of CHIR treatment (day 1),
NANOG dropped substantially in BAs but remained almost
unchanged in CPAs before downregulation occurred be-
tween days 1 and 3. A decline of OCT4 expression was
also delayed in CPAs (Figure 3F).
Regarding the metabolic activity, induction of differenti-
ation of CPAs resulted in a steep DO drop from 100% to
65% in 24 hr, whereas a moderate reduction to 85%
occurred in BA differentiation (exemplary depicted in Fig-
ure S2). Accordingly, the pH dropped from 7.5 to 6.9 in
CPA but only to 7.2 in BA differentiation. Thus, although
differentiation cultures were initiated at equivalent cellCBiPS2 at 7.5 mM CHIR confirmed the robustness of the established
day 10–13 EBs (E; NKX2.5 in yellow, a-actinin and cTNT in red, DAPI
B-derived CBiPS2 cells specific to respective sarcomeric proteins.
orts j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 The Authors 1135
Figure 2. Protocol Scale Up to Rotated Erlenmeyer Flasks
(A) Culture scheme in flasks rotated at 75 rpm.
(B) Microscopic assessment of NKX2.5-GFP expression in EBs on day 13 of differentiation in response to 7.5 mM CHIR.
(C) Immunofluorescent staining specific to a-actinin and cTNT on EB sections (top) and dissociated/plated cells derived thereof (bottom).
(D) Flow cytometry on day 7–10 revealed 55% of GFP+ (n = 5 of four independent experiments; mean ± SEM).
(E) Representative flow cytometry histograms of day 10 EB-derived cells.
See also Figure S1.
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overall metabolic activity was substantially higher in
CPAs in the presence of CHIR and remained higher
compared with differentiation processes of BAs during
IWP2 treatment and thereafter (Figure S2).1136 Stem Cell Reports j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 ThRobust upregulation of primitive streak markers Bra-
chyury T (T) (Gadue et al., 2006) and MIXL1 (Davis et al.,
2008) was observed after CHIR treatment (day 1), irrespec-
tive of aggregate origin, suggesting equivalent progression
of early differentiation in both conditions (Figure 3F). Ae Authors
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of mesoderm and cardiovascular cell-fate determination
(Bondue et al., 2008; David et al., 2008), and TBX3, pro-
moting early lineage (Esmailpour and Huang, 2012), mes-
endoderm (Weidgang et al., 2013), and CM specification
(Hoogaars et al., 2007). Upregulation of both genes was
more rapid in differentiating BAs (which ultimately failed
to form CMs) preceding expression in CPAs by 24–48 hr
(Figure 3F). Subsequently, upregulation of the early cardiac
progenitor markers ISL1 (Lui et al., 2013) and NKX2.5 (El-
liott et al., 2011) was almost exclusively observed in CPA
differentiations, consistent with the GFP expression. On
the other hand, GATA4 expression, a gene involved in car-
diac mesoderm (Sepulveda et al., 1998), as well as endo-
dermal lineage specification (Agarwal et al., 2008), was
highly equivalent in cells from both expansion strategies
(Figure 3F).
Directed Differentiation Enabled up to 85% CM
Induction andGeneration of 40Million CMs in 100ml
Scale
Focusing on CM formation, CPA-based differentiation pro-
cesses were analyzed in more detail. Upregulation of cTNT
(TNNT2) and a-MHC (MYH6) was observed by qRT-PCR
from day 5 onward (Figure 4A) in line with contracting
EBs from days 6 and 7 onward (data not shown). Interest-
ingly, a-MHC expression dropped when comparing day 7
versus day 10 samples, whereas b-MHC (MYH7), a marker
of CMsmaturation (Lundy et al., 2013), showed robust up-
regulation (Figure 4A).
At endpoint analysis (day 10), the vast majority of EBs
were bright GFP+ (Figure 4B) and contracting (Movie S1).
On average, 62.9% ± 7.3% GFP+ and 68.6% ± 8.7% cTNT+
cells were observed in three individual bioreactor runs
(53.9%–84.1%; Figure 4C and Table 1). When multiplied
with total cell yields, on average, 40 million CMs were
observed per process (Figure 4C), whereby more than 50
million CMs were generated in individual runs. Flow cy-
tometry for sarcomeric markers a-actinin, MHC, and the
cell surface marker SIRPa showed CM content of up 85%
CMs at process endpoint (Figure 4E). This observation
was further confirmed by immunofluorescence staining
on EB sections or EB-derived, seeded cells displaying typical
cross-striations (Figure 4D).
To substantiate the robustness of the C-perfusion-based
differentiation, additional experiments were performed us-
ing hHSC_F1285T_iPS2 cells (Hartung et al., 2013). The
CPA formation pattern of the hiPSC line (Figure S4A and
S4B) was highly equivalent to the HES3 NKX2-5eGFP/w
pattern (Figures 3A and 3B), resulting in an average aggre-
gate size of 531.6 ± 35.3 nm before differentiation (day 0;
Figure S4B). The subsequent cardiac differentiation led to
homogeneously contracting EBs (Movie S2). On average,Stem Cell Repthree independent runs revealed 53.2% ± 16.4% positivity
forMHC, 58% ± 30.3% cTNT, and 51.2% ± 14.6% a-actinin
(Figure S4C; range, 27.2%–83.5%; MHC, 27.7%–88.3%
cTNT; Table 1).
Electrophysiological andPharmacological Assessment
Confirms Formation of Functional CMs, which Can Be
Directly Applied for Tissue Engineering
Reactor-derived CMs were seeded onto MEAs to measure
field potentials in the presence of chronotropic and ar-
rhythmogenic drugs. Consistent with published data
(Mandel et al., 2012), we have detected a positive chrono-
tropic response by the beta-adrenergic agonist isoproter-
enol (Figure 5A). The class I antiarrhythmic compound
quinidine, known to have complex interactions with
ion channels, induced reversible spike amplitude reduc-
tion and prolonged the field potential duration (FPD) at
10 mM (Figure 5B), in line with recent findings (Braam
et al., 2010; Harris et al., 2013). The class IV antiar-
rhythmic drug verapamil exerts its action by blocking cal-
cium channels but is also a potent hERG blocker. The
compound induced a dose-responsive negative chrono-
tropic effect at 100 nM. This effect was more prominent
at 300 nM and accompanied by a shortening of the FPD
(Figure 5C), which most likely resulted from multiple
channel blocks, thereby compensating the known hERG
blocking effect, in agreement with clinical data (Braam
et al., 2010).
Electrophysiological properties were further analyzed by
whole-cell patch clamp recordings in the current clamp
mode. Cells were classified according to the shape of
their APs (Figure 5D). Thirty five of 41 cells (comprising
20 and 21 cells, respectively, derived from two indepen-
dent differentiations) displayed ventricular-like APs. Six
were classified as atrial-like (Figure 5E), whereas no AP pat-
terns indicating nodal-like CMs were identified. The data
were corroborated by comparing spontaneous versus
evoked APs applying short depolarizing current steps
(Figure S5).
Taken together, these pharmacological and electrophysi-
ological results underscore that our method led to the for-
mation of bona fide humanCMs, displaying typical charac-
teristics of early hPSC-derived cells (Navarrete et al., 2013).
Bioreactor-derived EBs were also used for the generation
of BCTs. After matrix solidification, EBs formed synchro-
nously contracting syncytia during the initial cultivation
phase (days 0–4; data not shown). The addition of fibro-
blasts to the EB/collagen-I matrix was not essential to
achieve tissue consolidation in contrast to a prior approach
using genetically enriched EBs, which consisted of >99%
CMs (Kensah et al., 2012). However, qualitative micro-
scopic comparison of tissue formation on day 21 suggested
slightly brighter NKX2.5-GFP intensity of constructs thatorts j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 The Authors 1137
Figure 3. Feeding Strategy Determines the Differentiation Outcome in Stirred Bioreactors
(A) Representative aggregate images generated from batch (top) and C-perfusion (bottom). The scale bar represents 1 mm.
(B) Significantly larger spheres were observed at C-perfusion 24 hr postinoculation (n = 3 bioreactor runs, mean ± SEM).
(C)Upregulatedgenes in C-perfusion-derived CPAs (top) andbatch-derivedBas (bottom)detectedbymicroarray analysis. Gene lists represent
the intersecting set of >2-fold upregulated and significantly regulated genes identified by RCUTAS and Qlucore Omics Explorer, respectively.
(legend continued on next page)
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fibroblasts (with HFF; n = 5) compared with the EB-only
group (withoutHFF, n =4; exemplary depicted in Figure 5F),
suggesting that HFF might support CMs persistence
in respective constructs. Furthermore, BCTs generated
with HFFs showed significantly higher contraction forces
compared with the control group (1.59 ± 0.2 versus 0.4 ±
0.23 mN) and a more physiological Frank Starling
mechanism, whereas no significant differences in passive
forces were observed between these experimental groups
(Figure 5G).
DISCUSSION
Focusing on critical culture parameters, we have developed
and upscaled the production of hPSC-derived CMs in
suspension culture and show their utility for tissue
engineering.
Chemical Wnt pathway modulators were recently
applied to direct cardiomyogenic differentiation of hPSCs
seeded on matrigel or the synthetic matrix Synthemax
(Gonzalez et al., 2011; Lian et al., 2012; Lian et al., 2013).
Disregarding upscaling limitations of monolayer cultures,
respective matrices might be a prerequisite for these proto-
cols to work. By successful transition to free floating aggre-
gates, we demonstrate that matrices and direct cell-to-sub-
strate contacts are dispensable, stripping away another
(costly) layer toward fully defined conditions.
In 2D, the generation of confluent monolayers ahead of
differentiation was noted to be critical for efficient cardio-
myogenesis (Lian et al., 2013). This suggests that the cell
density, which impacts on cell-cell contacts and the con-
centration of paracrine factors, plays a role. Lian et al.
(2013) thus provided cell numbers for monolayer inocula-
tion, but the resulting cell densities at the induction of dif-
ferentiationwere not noted. In contrast to surface-attached
cultures, cell density assessment and adjustment are
straightforward in suspension. Particularly in stirred biore-
actor scale, regular sampling allows closemonitoring of cell
counts and the assessment of other cell and aggregate prop-
erties, thereby ensuring good process definition and repro-
ducibility. Here, we initiated differentiation when cultures
reached a defined density of 0.33 3 106 cells/ml.
Although further investigations on the effect of cell density
are required, this ensures improved cross-platform and(D) Scheme of the defined expansion/differentiation protocol in bior
(E) Microscopic assessment of differentiating aggregates/EBs from da
only upon differentiation of C-perfusion-derived cells (right). The sca
(F) Gene expression analysis by qRT-PCR for markers of pluripotency (
(MESP1, GATA4, TBX3), and early cardiomyogenesis (ISL1, NKX2.5) com
3 independent bioreactor runs each).
See also Figures S1–S3 and Movie S1.
Stem Cell Repintercell line comparability and provides a valuable refer-
ence point.
Keeping all other parameters constant, the concentration
of the GSK3 inhibitor CHIR dictated the differentiation
outcome in our screening platform; 7.5 mM CHIR was
found to be optimal for cardiomyogenesis of hES3
NKX2.5-GFP cells in static and dynamic suspension culture
and was also applicable to two independent hiPSC lines. In
hESCmonolayers, 10 mMCHIRwas found to be optimal for
inducing primitive streak markers, mesoderm, and ulti-
mately cardiomyogenesis (Gonzalez et al., 2011), whereas
12 mM worked best in a related setup (Lian et al., 2012,
2013). Here CHIR concentrations >7.5 mM significantly
reduced the CM content and overall cell yields, suggesting
differential activity of GSK3 in suspension versus mono-
layer cultures. Alternatively, or in addition, the activity of
other canonical Wnt pathway components and/or other
pathways effecting cardiomyogenesis might differ in 3D
versus 2D.
Numerous studies have suggested an impact of a defined
sphere size on hPSC lineage differentiation. In microwell
plates, for example, 1,000 hESCs per aggregate differenti-
ated more efficiently into CMs compared with 100 or
4,000 hESCs per aggregate, respectively, whereby the size-
dependent formation of definitive endoderm was found to
trigger cardiac mesoderm induction by paracrine factors
(Bauwens et al., 2011). In hydrogel microwells, cardiogene-
sis was enhanced in EBs of 450 mm diameter, whereas
endothelial cell differentiation was increased at 150 mm,
apparently due to EB size-dependent expression of nonca-
nonicalWNTs (Hwanget al., 2009). In simple, agarose-based
microwells, Dahlmann et al. generated defined sphere
batches ranging from666 to 2,666hESCsper aggregate (rep-
resenting 185 to 270 mmmean diameter; J. Dahlmann, per-
sonal communication), respectively, followed by aggregate
harvest and differentiation in dynamic suspension (Dahl-
mann et al., 2013). Although the initial aggregate size had
an impact on hPSC growth kinetics and subsequently on
overall cell and CM yields, the resulting CM content re-
mained in a relativenarrow rangeof40%–50%at all aggre-
gate sizes tested (Dahlmann et al., 2013).
Despite the excellent experimental utility of culture plat-
forms generating uniform aggregates or colony patterns,
respective studies often ignore culture aspects such as the
overall cell density or lack informative controls of mixedeactors.
ys 1 to 5 (left) and GFP fluorescence on day 7, which was discovered
le bar represents 1 mm.
NANOG, OCT4), primitive streak (T-brachyury and MIXL1), mesoderm
paring differentiation of BAs (gray columns) and CPAs (green) (n =
orts j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 The Authors 1139
Figure 4. Characterization of Cardiomyogenesis in Cyclic Perfusion-Initiated Differentiations Revealed an Average Production of
40 3 106 CMs per Bioreactor Run, with >60% Average and up to 85% CM Content
(A) Gene expression analysis by qRT-PCR for cardiac specific markers over time (n = 3 independent bioreactor runs).
(B) Microscopic assessment of NKX2.5-GFP transgenic HES3 on day 10 of differentiation shows homogenous GFP expression in nearly all EBs.
(legend continued on next page)
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Table 1. Overview of CPA Differentiations
Run Cell Line
Cells per Milliliter Positive Cells (%)
Day 0 Day 10 NKX2.5 cTNT MHC a-Actinin
1 HES3 NKX2-5eGFP/w 3.00 3 105 4.40 3 105 69.1 84.1 81.1 89.6
2 HES3 NKX2-5eGFP/w 3.00 3 105 1.00 3 106 71.3 53.9 53.2 ND
3 HES3 NKX2-5eGFP/w 3.00 3 105 4.00 3 105 50.8 67.8 66.8 67.3
4 hHSC_1285T_iPS2 3.00 3 105 8.88 3 105 NA 27.7 27.2 26.1
5 hHSC_1285T_iPS2 3.00 3 105 1.20 3 106 NA 88.3 83.5 76.7
6 hHSC_1285T_iPS2 3.00 3 105 1.25 3 106 NA ND 48.8 50.7
NA, not applicable; ND, not determined.
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Scalable Generation of hPSC Cardiomyocytessphere sizes. Comparing EB formation methods, such as
random induction in suspension versus size-controlled
spin EBs, Hong et al., (2010) noted that, despite a potential
influence of the EB size, cell density-dependent, and (co)
culture-dependent medium, conditioning dominantly
defined hESC hematopoietic differentiation. Generating
defined EBs by forced aggregation of mouse ESCs instruc-
tive clues on differentiation were rather induced by
rotation speed-dependent hydrodynamic forces, whereas
minor, if any, EB size-dependent effects were observed (Kin-
ney et al., 2012).
In our static 12 wells, the average aggregate diameter was
210 mm, representing a relatively large spread of 100–
400 mm in each well, typical of random aggregation. How-
ever, at 7.5 mM CHIR, aggregates of all shapes and sizes
differentiated into contracting, GFP+ EBs, whereas, at sub-
optimal CHIR concentrations, GFP expression was reduced
or failed in respective wells, again without apparent aggre-
gate/EBs size correlation. In stirred Erlenmeyer Flasks, the
mean aggregate diameter was 400 mm (300–600 mm),
and in bioreactors, at C-perfusion, it was 450 mm
(350–600 mm), representing about double the mean
diameter in 12 wells. These culture-dependent disparities
were still compatible with efficient CM formation applying
the same preoptimized differentiation protocol. In
contrast, following batch expansion, cardiomyogenesis
completely failed in repeated bioreactor runs, although
the mean aggregate diameter of 300 mm (150–450 mm)
was within the range of successful conditions.
Taken together, our cross-platform findings suggest that
the initial aggregate size before induction of differentiation(C) Relative (top) and total (bottom) numbers of NKX2.5-GFP- or cT
bioreactor runs).
(D) Immunofluorescent staining specific to sarcomeric proteins on HES
derived, plated cells from EBs dissociated on day 10 (bottom; the sca
(E) Representative flow cytometry data of EB-derived cells.
See also Figure S4.
Stem Cell Repper se is not the dominant factor determining cardiac dif-
ferentiation outcomes in suspension culture. Within a
given size range, variations can be tolerated.
In the hPSC expansion phase, batch feeding was applied
in static 12-well dishes and in stirred Erlenmeyer flasks,
whereas in bioreactors, (cyclic) perfusion feeding led to suc-
cessful cardiac differentiation. This demonstrates that
different cell feeding protocols ahead of differentiation
were compatible with subsequent cardiomyogenesis.
In the bioreactor setup the spatiotemporal pattern of
aggregate development was the major determinant of sub-
sequent differentiation results. We and others have shown
that the pattern of PSC aggregation and further sphere
development can be controlled well in stirred bioreactors
by means of the inoculation density, the impeller design,
and the stirring speed (Hunt et al., 2014; Olmer et al.,
2012; Schroeder et al., 2005), including the on/off patterns
applied in this study. In addition to the feeding-dependent
differences of the culture milieu, the striking distinction
was the continuous growth of initially small aggregates at
batch, whereas at C-perfusion relative large CPAs were
formed at 24 hr with a minor increase in size thereafter.
Although global profiling revealed rather uniform gene
expression patterns typical of pluripotent cells under
both expansion conditions, expression of the key
morphogen BMP2 was highly upregulated in C-perfusion
cultures. Modest BMP2 and BMP4 expression is suggested
to act as an endogenous prodifferentiation signal in
hESC, although these levels are insufficient to promote dif-
ferentiation at pluripotent culture conditions (Teo et al.,
2012). However, upon differentiation, the dominant roleNT-positive cells on day 10 of differentiation (n = 3 independent
-derived EB sections (top; the scale bar represents 100 mm) and iPS-
le bar represents 50 mm).
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Figure 5. Electrophysiological and Pharmacological Characterization and Generation of BCT from Bioreactor-Derived EBs
(A–C) MEA-derived field potentials (FPs) revealed a positive chronotropic response by the beta-adrenergic agonist isoproterenol at 2 mM
(A), prolonged FP duration at >1 mM quinidine (Q), and reduced spike amplitude at 10 mM (B), and a negative chronotropic response
accompanied by a shortening of the FP duration in response to 300 nM verapamil (V) treatment (C). Effects were reversible by washout (W)
(baseline [B]). n = 2 independent experiments.
(D) Representative recordings of a spontaneously active CM displaying a ventricular-like AP (top) and evoked APs representing ventricular-
and atrial-like cells (bottom). Arrows in the bottom panels denote initial voltage responses to intracellular stimulation by short depo-
larizing current steps (left: 600 pA, 1 ms; right: 900 pA, 1 ms).
(E) Distribution of atrial- and ventricular-like cells derived from two differentiations.
(F) BCTs generated from EBs without (w/o, black lines/columns) or with (w, red) HFF on day 21. The scale bar represents 1 mm.
(legend continued on next page)
1142 Stem Cell Reports j Vol. 3 j 1132–1146 j December 9, 2014 j ª2014 The Authors
Stem Cell Reports
Scalable Generation of hPSC Cardiomyocytes
Stem Cell Reports
Scalable Generation of hPSC Cardiomyocytesof BMP signaling on posterior primitive streak and subse-
quently onmesoderm formation in hPSCs was recently un-
derscored (Loh et al., 2014). The upregulation of BMP2 as
well as CDX4 (involved in anteroposterior axis specifica-
tion regulated by Wnt activity; Hikasa et al., 2010) in
CPAs might suggest the priming of these cells for meso-
derm differentiation ahead of CHIR supplementation.
Loh et al. (2014) further noted the necessity to neutralize
endogenous BMP to eliminate mesoderm induction of
hPSCs. The upregulation of BMPER (BMP endothelial cell
precursor derived regulator), an established antagonist of
BMP2, BMP4, and BMP6 (Moser et al., 2003), in BAs (bot-
tom panel in Figure 3C) might act as a neutralizing signal
and, at least in part, explain the entire lack of cardiomyo-
genesis upon differentiation of these cells.
The control of cardiac differentiation by BMP signaling is
well established (Laflamme and Murry, 2011). However,
the role of autocrine/paracrine hPSC-derived BMP agonists
and antagonists in modulating WNT pathway controlled
differentiation is not well studied. Although future investi-
gations on this are necessary, our data indicate the impor-
tance of this interplay.
However, primitive streakmarker expression, including T
andMIXL, was clearly present in BA-derived EBs after CHIR
supplementation, suggesting that mesendodermal differ-
entiation proceeds normally. Our data suggest that the
temporal shift in the expression of key lineage transcrip-
tion factors, such as MESP1 and TBX3, in CPA compared
with BA cultures might underlie the divergence in differen-
tiation outcomes.
We further found that the expression of 6 of 13 tested
subtypes of the major metallothionein isoforms 1 and 2
(MT1, MT2) was upregulated in BAs. Since MTs bind to
metal ions, a role of these proteins in hematopoietic cell
proliferation and differentiation was suggested, but regu-
lation of MTs expression by numerous stimuli, including
oxidative stress (Takahashi, 2012), has been described.
In mouse ESCs, upregulation of MT1 was discovered after
addition of the p38 mitogen-activated protein kinase in-
hibitor PD169316 at LIF starvation-induced stress condi-
tions (Duval et al., 2006). Overexpression of MT1 was
notably sufficient to protect mESC from differentiation-
induced apoptosis. To date, little is known about the
functional role of MT in human PSCs, but we hypothesize
that the feeding-induced fluctuation of the culture envi-
ronment at batch conditions induces MT expression,
as compared with more homogeneous conditions at
C-perfusion. Although further investigation is required,(G) Force measurements of BCTs generated with HFF showed significa
Frank Starling mechanism (top left) compared with BCTs without HF
right). n = 4–5 of independent BCTs.
See also Figure S5.
Stem Cell Repmetallothionein might thus present an interesting marker
of stress response in hPSC culture. In this context, it
is noteworthy that the stress-related genes HSPA1A
and HSPA1B (HSP70 protein) were both found to be
2-fold upregulated in BAs compared with CPAs (data
not shown).
Following fundamental analysis of pharmacological and
electrophysiological features of suspension-derived CMs,
we have demonstrated direct applicability of bioreactor-pro-
ducedEBs for tissueengineering.WhileBCTgenerationfrom
undissociated, contracting spheres was recently shown, this
required genetic enrichment of CMs before tissue formation
(Kensah et al., 2012). On the other hand, enrichment to
99% CM purity was incompatible with direct BCT genera-
tion, but required 15% fibroblast addition to remodel the
initial collagen I matrix and hence support tissue formation
(Kensah et al., 2012). Here, we show that the80%CMcon-
tent resulting from our differentiation protocol was directly
compatible with the production of functional tissues, sug-
gesting that residual non-CMs within EBs provided struc-
tural support. A detailed assessment of the phenotype and
features of respective non-CMs is currently in progress.
Taken together, we show that bioreactor-controlled
programs of hPSC culture can be used to direct the subse-
quent fate of hPSCs on differentiation. As recently noted,
it is now necessary to focus on the improvement of mass
suspension culture for hPSC production and differentiation
(Chen et al., 2014). Our study provides a substantial step
along this path.EXPERIMENTAL PROCEDURES
Cell Culture
HES3 NKX2-5eGFP/w (Elliott et al., 2011), hCBiPS2 (Haase et al.,
2009), and hHSC_F1285T_iPS2 (Hartung et al., 2013) were main-
tained at standard conditions on MEFs. Before transition to sus-
pension culture, cells were accutase-treated (PAA Laboratories)
and seeded at 5 3 104 cell/cm2 on Geltrex-coated flasks either in
KnockOUT-SR medium (Life Technologies) conditioned with
MEFs or in mTeSR1 (STEMCELL Technologies) supplemented
with 10 mMY-27632 for 24 hr.Mediumwas replaced daily, and cells
were passaged twice per week.
For the inoculation of suspension culture, dissociation into sin-
gle cells was performed by accutase treatment for 5min at 37C fol-
lowed by dilution to 3.3 3 105 cells/ml in mTeSR1 plus 10 mM
Y-27632 and seeding into 12-well suspension plates (Greiner-
BioOne) or Erlenmeyer flasks (125 ml scale; VWR-International)
in 1.5 ml/well or 20 ml/flask, respectively. Flasks were agitated at
75 rpm (orbital-shaker, Infors-HT).ntly higher active forces (Lmax; top right) and a more physiological
F, but no significant difference in passive forces (bottom left and
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ulated as described previously (Olmer et al., 2012) (Supplemental
Experimental Procedures). For subsequent expansion strategies,
see the Results.
Differentiation of resulting aggregates was induced on day
0 (4 days after single cell inoculation) using CHIR99021 (synthe-
sized by the Institute of Organic Chemistry, Leibniz University
Hannover or purchased from Millipore) at indicated concentra-
tions for 24 hr. On day 3, IWP2 (Tocris) was added at 5 mM for
48 hr. During the differentiation, cells were kept in RPMI1640
(Life Technologies) supplemented with B27 (minus insulin). Me-
dium was entirely replaced on days 0 (+CHIR), 1, 3 (+IWP2 or
IWR1), and 5 applying a volume of 3, 20, or 100 ml depending
on the respective culture format, i.e., 12-well dish, Erlenmeyer
flask, or stirred bioreactor. Aggregates were cultured in RPMI1640
supplemented with B27 from day 7 onward.
Aggregate or EB samples were monitored by light microscopy;
images were captured (AxiovertA1; Zeiss) and processed in
AxioVision (Zeiss) to define diameter and size distribution. Mean
diameters represent the arithmetic average of 400–700 independent
spheres. For cell seeding, samples were dissociated by 1mg/ml colla-
genase B (Roche) for 15–60min (progressingwith differentiation) at
37C (Maltsev et al., 1993; Zweigerdt et al., 2011).
For standardmethods and prepublished techniques, see the Sup-
plemental Experimental Procedures.Statistics
Data are presented as mean ± SEM. Unless otherwise noted,
statistical significance was calculated using Student’s t tests. To
take account of multiplicity in group comparisons, one- or two-
way ANOVA followed by Bonferroni’s posttest was conducted.
Statistical significance was assigned as *p < 0.05, **p < 0.01, and
***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and two movies and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2014.09.
017.
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